முதலீட்டாளர் விளக்கக்காட்சி
டீல்
டீல் மதிப்பு₹350 கோடி
டீல் vs வணிகம்₹350 Cr capex is 0.34x TTM revenue (₹1,024 Cr) and 53.9% of Net Worth (₹649 Cr); adds 75M pens overseas to existing 75M domestic capacity.
சொந்த வருவாயுடன் ஒப்பிடும் அளவு0.34×
செயல்படுத்தும் காலம்3.0 ஆண்டு
அடிப்படை தரம்A
AI முன்கணிப்புகள்
வருவாய் உயர்வு (முதல் ஆண்டு / நிலையான)12.0% / 58.0%
EPS உயர்வு72.0%
அப்சைடு பேஸ் / புல் / பேர்45.0% / 95.0% / -35.0%
கால எல்லை24-36 மாதங்கள்
உண்மையான சந்தைப் பதிவு
நுழைவு — அடுத்த நாள் தொடக்கம் (30 அக். 2026)₹3110.6
சமீபத்திய முடிவு விலை (12 நவ. 2026)₹3122.8
தொடங்கியதிலிருந்து வருமானம்+0.4%
α vs Smallcap 250-6.9%
α vs சொந்தத் துறை90+ நாட்கள் வைத்திருந்த பிறகு மட்டுமே காட்டப்படும் — பிளாஸ்டிக் பொருட்கள் இடைநிலை -6.1%, முதிர்ச்சியடைந்த 17 பரிந்துரைகளின் அடிப்படையில்
நேர்மறைகள்
- Strategic pivot from standard precision injection plastics to high-margin healthcare/medical devices (Healthcare surged 78% YoY in Q2 FY27 to ₹175.1 Cr, now >54% of revenue).
- Expansion into Abu Dhabi (75M pens capacity) targets booming global GLP-1 and insulin delivery device demand, effectively doubling overall pen manufacturing capacity.
- Superior operating profitability: EBITDA margins expanded to 31.9% in Q2 FY27, with gross margins benefiting from a structural shift toward proprietary IP-led pen platforms.
- Prudent balance sheet with ROCE at 30.0% and Debt/Equity at 0.27, supported by CARE upgrading short-term ratings to CARE A1+.
அபாயங்கள்
- Extreme customer concentration: A handful of multinational pharmaceutical clients account for the majority of healthcare revenue, limiting bargaining leverage.
- Extended regulatory and commissioning gestation: Pharma client audits, tech-transfers, and validation delays could defer commercial dispatch by 12-14 months.
- Valuation re-rating headroom is constrained: Trailing P/E stands at 79.5x (versus plastics peer median of 28.7x), leaving zero margin of safety for execution stumbles.
- Persistent drag from legacy consumer plastics division (-14% YoY in Q2 FY27) due to subdued international demand.
முழு AI சுருக்கம்
Shaily Engineering Plastics (SHAILY) - Detailed Research Report
Analysis Date: 2026-10-29 | Current Price: ₹3,056.30 | Market Cap: ₹14,007 Cr | Trailing P/E: 79.5x
1. Catalyst Evaluation & Ramp-Aware Execution Math
Shaily announced a dual catalyst on October 29, 2026: strong Q2 FY27 operational earnings and a substantial international expansion plan.
- Capex Details: Planned investment of AED 130–150 million (~₹350 Cr) in Abu Dhabi to establish a medical device facility with an annual capacity of 75 million pens focused on the global GLP-1 drug delivery surge. Concurrently, a domestic 25 million pen expansion is undergoing regulatory validation.
- Capital Context: At ₹350 Cr, the capex represents 34% of TTM revenue (₹1,024 Cr) and ~54% of current Net Worth (₹649 Cr). This is not an unmanageable mega-order, but a well-calibrated capacity doubling (expanding from 75M domestic capacity to 175M total pens).
- Execution Timeline: Setting up medical clean rooms, securing regional and global regulatory approvals (USFDA/EMA DMF filings), and passing client tech-transfers in Abu Dhabi realistically requires 2.5 to 3.0 years.
- Ramp Arithmetic:
- Year 1 (FY27/28): Zero contribution from Abu Dhabi. Near-term growth will stem from commercializing the 25M domestic validation capacity and organic healthcare traction. Anticipated incremental top-line uplift: ~12% (adding ~₹125–150 Cr).
- Steady State (Year 3-4, FY30): Full commercial utilization of 75M Abu Dhabi pens + 25M domestic pens. Assuming realization of ₹70–90 per pen, incremental revenue potential is ₹600–750 Cr (+58% over TTM revenue of ₹1,024 Cr).
- Earnings Impact: At operating margins of 30-31% and NPM of ~18-19%, incremental steady-state PAT would be ~₹115-135 Cr. Adding to annualized base PAT (~₹230 Cr) yields a steady-state PAT of ~₹350-370 Cr, representing a ~72% EPS uplift.
2. Industry Dynamics & Capital Intensity
- Capital Intensity: Medium. Precision moulding tools and clean-room facilities require moderate capital investment, but the business maintains a fixed asset turnover of ~2.0x.
- Execution Difficulty: High. Producing drug delivery mechanisms (such as GLP-1 pens and auto-injectors) requires micron-level tolerance. Any failure in dose accuracy halts shipments, and regulatory qualification cycles take 12-14 months.
- Structural CAGR: The global injectable drug delivery device market, particularly for diabetes and anti-obesity GLP-1 agonists, is expanding at ~18-20% CAGR, supporting multi-year volume absorption.
3. Fundamental Quality & SEPA Filter Checks
- EPS & Revenue Momentum: High fundamental quality. Revenue expanded from ₹644 Cr in FY24 to ₹990 Cr in FY26. Q2 FY27 consolidated revenue reached ₹319.5 Cr (+24% YoY), driven by an exceptional 78% surge in Healthcare (₹175.1 Cr), while PAT grew 20% YoY to ₹61.3 Cr.
- Margin Profile: Operating margins have expanded from 18.2% in FY24 to 28.2% in FY26, reaching 31.9% in Q2 FY27 due to proprietary IP platforms.
- Balance Sheet: Prudent leverage with D/E at 0.27 (Debt of ₹175 Cr vs Net Worth of ₹649 Cr) and healthy ROCE of 30.0%. CARE upgraded short-term facility ratings to CARE A1+.
- Promoter Holding: Sits at 41.09%, remaining stable over recent quarters and above the 35% risk threshold.
4. Valuation Context & Calibrated Scenarios (24–36 Month Horizon)
Shaily trades at 79.5x trailing P/E (and ~58x annualized FY27 run-rate PAT of ₹245 Cr). While peers trade at a median of 28.7x, they are primarily commodity plastic moulders, whereas Shaily is successfully pivoting into a medical CDMO device player.
- Bull Case (+95% Upside): Abu Dhabi unit is commissioned within 24 months; GLP-1 demand accelerates beyond expectations; consolidated FY29 PAT reaches ₹460 Cr; valuation multiple consolidates at ~60x P/E.
- Base Case (+45% Upside): Abu Dhabi plant commences commercial dispatches by Year 3; domestic healthcare grows at 25% CAGR; FY29 PAT reaches ₹370 Cr; multiple contracts to a sustainable 55x P/E, yielding an equity value of ~₹20,350 Cr (~₹4,440/share).
- Bear Case (-35% Downside): Regulatory delays defer Abu Dhabi commercialization beyond 3.5 years; anchor customer off-take drops; consumer division continues dragging top line; FY29 PAT stagnates at ₹220 Cr; P/E decompresses sharply toward 40x.
5. தீர்ப்பின் காரணம்
Shaily fulfills the operational criteria of an emerging high-quality CDMO/medical device company (30% ROCE, accelerating healthcare mix, expanding operating margins). However, because the current market valuation (₹14,007 Cr, 79.5x trailing P/E) already prices in flawless near-term execution, and because the ₹350 Cr Abu Dhabi expansion will require 2.5–3 years to reach steady-state profitability, the verdict is POSSIBLE rather than STRONG_CANDIDATE.
2026-10-29 நிலவரப்படி பகுப்பாய்வு (விலை ₹3056.30) · AI ஆய்வு, முதலீட்டு ஆலோசனை அல்ல.
பின்தொடர்Telegram
